Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Regenerative Medical Technology (RMTG) over the last 5 years, with Q3 2025 value amounting to $77330.0.

  • Regenerative Medical Technology's Change in Receivables rose 103420.36% to $77330.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $83000.0, marking a year-over-year increase of 217240.95%. This contributed to the annual value of -$1351.0 for FY2024, which is 9476.56% up from last year.
  • As of Q3 2025, Regenerative Medical Technology's Change in Receivables stood at $77330.0, which was up 103420.36% from $20370.0 recorded in Q2 2025.
  • Over the past 5 years, Regenerative Medical Technology's Change in Receivables peaked at $77330.0 during Q3 2025, and registered a low of -$51500.0 during Q2 2023.
  • Its 5-year average for Change in Receivables is $5887.2, with a median of -$4426.5 in 2021.
  • As far as peak fluctuations go, Regenerative Medical Technology's Change in Receivables tumbled by 132901.33% in 2022, and later skyrocketed by 103420.36% in 2025.
  • Over the past 5 years, Regenerative Medical Technology's Change in Receivables (Quarter) stood at -$2554.0 in 2021, then plummeted by 1329.01% to -$36497.0 in 2022, then surged by 69.71% to -$11055.0 in 2023, then grew by 24.01% to -$8401.0 in 2024, then soared by 1020.49% to $77330.0 in 2025.
  • Its last three reported values are $77330.0 in Q3 2025, $20370.0 for Q2 2025, and -$6299.0 during Q1 2025.